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Brief Definit ive Report
Broadly neutralizing monoclonal antibodies 
(bnmAbs) that target the structurally conserved 
CD4 binding site (CD4-BS) bind with high af-
finity to Env and neutralize diverse HIV-1 iso-
lates, irrespective of their clade (Wu et al., 2010, 
2011; Diskin et al., 2011; Scheid et al., 2011). 
Despite the isolation of these anti–CD4-BS 
bnmAbs from distinct HIV+ subjects, they share 
common genetic and structural features, which 
are critically important for their unique neutral-
izing properties (Scheid et al., 2011; Wu et al., 
2011). So far, four classes of anti–CD4-BS 
broadly neutralizing antibodies (bNAbs) have 
been defined: b12, HJ16, VRC01, and 8ANC131 
(Kwong and Mascola, 2012). Of particular in-
terest for HIV vaccine development are the 
VRC01 class antibodies because of their ex-
ceptional neutralization potency and breadth. 
Their VH domains are derived from VH1-2, in 
contrast to the 8ANC131 class antibodies whose 
VH domains are derived from VH1-46 (Scheid 
et al., 2011) and b12 whose VH is derived from 
VH1-03 (Hoot et al., 2013). The currently 
known VRC01 class antibodies (such as VRC01, 
NIH45-46, 3BNC60, and 12A21), were isolated 
from distinct HIV+ subjects infected with dif-
ferent viruses and display up to 57% diversity in 
VH and up to 65% diversity in VL sequences; 
Wu et al., 2010, 2011; Scheid et al., 2011; West 
et al., 2012; Table S1). Despite this high degree 
of amino acid sequence diversity, they share 
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Broadly neutralizing antibodies (bnAbs) against HIV are believed to be a critical component 
of the protective responses elicited by an effective HIV vaccine. Neutralizing antibodies 
against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glyco-
protein (Env) are capable of inhibiting infection of diverse HIV strains, and have been 
isolated from HIV-infected individuals. Despite the presence of anti–CD4-BS broadly neu-
tralizing antibody (bnAb) epitopes on recombinant Env, Env immunization has so far failed 
to elicit such antibodies. Here, we show that Env immunogens fail to engage the germline-
reverted forms of known bnAbs that target the CD4-BS. However, we found that the 
elimination of a conserved glycosylation site located in Loop D and two glycosylation  
sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells  
expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, 
VRC01 and NIH45-46. Our results offer a possible explanation as to why Env immunogens 
have been ineffective in stimulating the production of such bNAbs. Importantly, they 
provide key information as to how such immunogens can be engineered to initiate the 
process of antibody-affinity maturation against one of the most conserved Env regions.
© 2013 McGuire et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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and included two additional VRC01 class anti–CD4-BS 
bnmAbs; 3BNC117 and 12A21 (Scheid et al., 2011; Table S2). 
The mature versions of these mAbs recognize between 92% 
(3BNC60) and 71% (12A21) of Envs tested. In contrast, there 
was no detectable binding to these Envs by the germline- 
reverted versions of these antibodies. We note that although 
the accessibility of the CD4-BS by CD4 and anti–CD4-BS 
antibodies is restricted by the V1, V2, and V3 variable domains 
of Env and associated N-linked glycosylation sites (NLGS; 
Wyatt et al., 1993; Ly and Stamatatos, 2000; Saunders et al., 
2005), the elimination of these regions did not result in Env-
recognition by the germline-reverted anti–CD4-BS bnAbs 
studied here.
The interactions between Env and the germline-reverted 
forms of anti–CD4-BS bnAbs are commonly investigated using 
soluble forms (IgG or scFv) of antibodies (Xiao et al., 2009; 
Wu et al., 2010, 2011; Hoot et al., 2013; Scheid et al., 2011). 
This interaction may not accurately reflect the interaction of 
Env with the corresponding membrane-anchored BCRs on 
B cells. Conceivably, certain recombinant Envs can bind weakly 
to, and cross-link the germline-reverted BCRs of VRC01 class 
anti–CD4-BS bNAbs and activate the corresponding B cells. 
If that is the case, then the deficiency in the development of 
such antibodies during immunization could not be explained 
by a lack of recognition of their germline-reverted BCRs by 
Env. Here, we investigated the interaction between recom-
binant HIV Env and B cells expressing the germline-reverted 
BCR versions of VRC01 class antibodies to identify poten-
tial roadblocks during the earliest steps of B cell activation. 
We report that in order for Env to engage and activate B cells 
expressing germline-reverted NIH45-46 and VRC01 BCRs, 
specific N-linked glycosylation sites (NLGS) located at key 
regions of Env must be absent (something that only rarely 
occurs during natural HIV-infection).
structural similarities that allow them to recognize the CD4-
BS in a manner very similar to each other and to the CD4 re-
ceptor (Scheid et al., 2011; Wu et al., 2011). That interaction 
is primarily through the VH antibody domains; however, the 
light chains of VRC01 class antibodies also make important 
contacts with Env. This contrasts with b12, which appears to 
interact with Env exclusively through its heavy chain. The 
mode of Env interaction of HJ16 class antibodies is not yet 
known. An additional unique feature of the VRC01 class anti-
bodies is that they make contact not only with the gp120 outer 
domain, but also with the gp120 inner and bridging sheet do-
mains (Diskin et al., 2011; Scheid et al., 2011; Wu et al., 2011).
Only a fraction of those infected with HIV develop broadly 
neutralizing anti–CD4-BS antibodies (Lynch et al., 2012). 
Despite the presence of anti–CD4-BS epitopes on recombi-
nant Env (Li et al., 2007; Binley et al., 2008; Sather et al., 2009; 
Mikell et al., 2011), Env immunization has so far failed to elicit 
such antibodies (Mascola and Montefiori, 2010; Stamatatos, 
2012). The reasons why such antibodies are not elicited by Env 
immunization, and are only rarely generated during natural 
HIV infection, are currently not well understood. Identifying the 
roadblocks that prevent the generation of such antibodies and 
approaches to overcome these barriers will aid in the development 
of an effective HIV vaccine (Mascola and Montefiori, 2010).
The germline-reverted (unmutated) forms of VRC01 class 
anti–CD4-BS bnmAbs, do not recognize the recombinant Env-
derived bait protein used to isolate the B cells expressing the 
corresponding mature antibodies (Zhou et al., 2010; Scheid 
et al., 2011). We reported that the germline-reverted forms 
of two VRC01class antibodies, NIH45-46 (a clonal variant 
of VRC01; Scheid et al., 2011) and 3BNC60, fail to recog-
nize a large panel of recombinant Env derived from clades A, 
B, and C, the three most predominant clades worldwide (Hoot 
et al., 2013). In the current study, we expanded our Env panel 
Figure 1. Env binding to the mature and germline-
reverted NIH45-46 BCRs and B cell activation. (a) NIH45-46 
IgG binding to the indicated recombinant trimeric gp140 
Envs was measured by ELISA. (b) B cells expressing the ma-
ture (white bars) or germline-reverted (gray bars) NIH45-46 
BCR, as well as mock transfected cells (black bars), were in-
cubated with the indicated trimeric gp140 proteins, followed 
by incubation with a PE-labeled polyclonal anti-HIV IgG pool. 
The MFI of PE staining was determined in NIH45-46 BCR 
expressing cells identified by staining with APC-labeled 
monoclonal anti–human IgG. Error bars represent SD from 
the mean of two independent experiments. (c and d) B cells 
expressing the mature (c) or germline-reverted (d) NIH45-46 
BCR were loaded with Fluo-4 direct calcium indicator and 
stimulated with the indicated trimeric gp140 proteins. Black 
arrows in c and d indicate time of Env-addition. Data are 
representative of three independent experiments.
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BCRs were expressed by transfected B cells and both BCRs 
mediated comparable intracellular Ca2+ flux responses, after 
cross-linking by anti–human IgG F(ab)2 (unpublished data). 
A panel of diverse clade A, B, and C trimeric Envs that dis-
play a wide range of affinities for the mature NIH45-46 
(mNIH45-46) bound to B cells expressing the mNIH45-46 
BCR (Fig. 1, a and b). An Env with a point mutation (D368R), 
RESULTS AND DISCUSSION
To ensure that the binding specificities of soluble antibody 
forms are congruent with their BCR forms, we investigated 
how diverse Envs interact with B cell–expressed BCRs of 
mature and germline-reverted NIH45-46; one of the most po-
tent and broadly neutralizing VRC01 class antibodies (Scheid 
et al., 2011). Similar levels of mature and germline-reverted 
Figure 2. Removal of N-linked glycosylation sites from the 426c Env confers binding to germline-reverted NIH45-46 and VRC01. Binding of 
mature NIH45-46 (a, d, g, and j), germline-reverted NIH45-46 (b, e, h, and k), and germline-reverted VRC01(c, f, i, and l) IgG to trimeric gp140 
426c (a–c; wild type), 426c lacking the NLGS at position 276 (d–f; N276D), 426c lacking NLGS at positions 460 and 463 (g–i; N460D.N463D), or 426c 
lacking NLGS at positions 276, 460, and 463 (j–l; N276D.N460D.N463D) was measured by BLI. For mature and germline-reverted NIH45-46, black, red, 
orange, blue, and green lines represent 1.7 µM, 850 nM, 425 nM, 212 nM, and 106 nM of trimeric Env, respectively. For germline-reverted VRC01, black, 
red, orange, blue, and green lines represent 2 µM, 1 µM, 500 nM, 250 nM, and 125 nM of trimeric Env, respectively. Dashed gray lines represent the theo-
retical fit. The binding kinetic data (including experimental error) are summarized in Table S3.
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Figure 3. Removal of N-linked glycosylation sites from the 426c Env results in stimulation of the germline-reverted NIH45-46 and VRC01 BCRs. 
(a) B cells expressing the mature (white bars) or germline-reverted (black bars) NIH45-46 IgG BCR, were incubated with the indicated trimeric gp140 proteins, 
followed by incubation with a PE-labeled polyclonal anti-HIV IgG pool. The MFI of PE staining was determined in NIH45-46 BCR expressing cells identified by 
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from 426c, are suggestive of alleviation of steric constraints 
rather than changes in epitope conformation. Interestingly, the 
glNIH45-46 and glVRC01 did not bind the mutant lacking 
the 460 and 463 NLGS (Fig. 2, h and i). The mutant Envs lack-
ing the 276 NLGS or all three NLGS bound the glNIH45-46 
BCR (Fig. 3 a) and activated the corresponding B cells (in-
crease in tyrosine phosphorylation [Fig. 3, c and g] and Ca2+ 
flux [Fig. 3 j]). In agreement with our binding data for the 
glVRC01 (Table S3), which indicated stronger Env-binding 
affinities for glVRC01 than glNIH45-46, the ensuing B cell 
activation with these two Envs was stronger (Fig. 3, d, g, and k) 
than that observed with B cells expressing the glNIH45-46 
BCR (Fig. 3, c, g, and j).
Because the intensity of BCR signaling through the IgG 
form is stronger than through the IgM form (Wakabayashi 
et al., 2002; Horikawa et al., 2007; Waisman et al., 2007), we 
performed our studies with the IgG form, to ensure that any 
weak signaling induced by our Env proteins would be de-
tected. However, when germline BCRs are expressed on naive 
B cells, they are of the IgM or IgD classes. We confirmed that 
the signaling pattern through the IgM glNIH45-46 and 
glVRC01 BCRs mirrors that observed with the correspond-
ing IgG BCRs, but, as expected, the intensity of the signal is 
lower (Fig. 3, e, f, and h).
The aforementioned results suggest that the NLGS at po-
sition 276 plays a critical role in the binding efficiencies of 
mature and germline-reverted NIH45-46 and VRC01 with 
Env. Structural modeling suggests that this NLGS hinders anti-
body binding by interfering with the light antibody chain 
(Fig. 3 l). Our model indicates that the NLGS at position 463 
is not close enough to the antibody epitope to be a major player 
in this interaction. The model and the improved affinities of 
germline-reverted and mature NIH45-46 and VRC01 for the 
triple mutant over the single N276D mutant are consistent with 
the hypothesis that the glycan at 460 also limits the accessibil-
ity of the antibody; the fact that removal of 460 and 463 alone 
does not significantly improve germline-reverted affinity em-
phasizes that germline-reverted binding is dependent on re-
moval of the glycan at 276. The CDRL1 of mNIH45-46 and 
which greatly reduces the binding of anti–CD4-BS antibod-
ies, was included as a negative control. The Envs that bound 
the mNIH45-46 BCR also induced Ca2+ flux through this 
BCR (Fig. 1 c). We did not detect binding of these Envs 
to cells expressing the germline-reverted NIH45-46 BCR 
(glNIH45-46 BCR; Fig. 1 b), nor did we observe Ca2+ flux 
in these cells (Fig. 1 d). Similar lack of YU2 Env-binding to 
the germline-reverted VRC01 (glVRC01) BCR was recently 
reported (Ota et al., 2012).
Elimination of the Env variable regions 1, 2 or 3 did not 
result in germline antibody-Env binding (Table S2). However, 
accessibility of the CD4-BS is also limited by proximal NLGS 
(Schief et al., 2009). NLGS located in Loop D and V5 of gp120 
are of particular interest because they are located in two re-
gions of Env that modulate the neutralizing activities of VRC01 
class antibodies (Li et al., 2011). In fact, the light chains of the 
mature NIH45-46 and VRC01 antibodies contact the N-acetyl-
glucosamine residues at Asn 276 in loop D (Zhou et al., 2010; 
Diskin et al., 2011). We eliminated NLGS from these regions 
from the clade C Env 426c, which is recognized with high 
apparent affinity (10.6 nM) by mNIH45-46 (Fig. 1 a, Fig. 2 a, 
and Table S3). Elimination of the 276, the 460 and 463 (V5), or 
all three NLGS from 426c increased the binding of mNIH45-46 
(apparent affinities of 3.66 nM, 1.9 nM, and 18 pM, respec-
tively; Fig. 2, d, g, and j; and Table S3). The mutant Envs also 
bound more efficiently to mNIH45-46 BCR (Fig. 3 a) and 
induced increased B cell activation, as indicated by increases 
in tyrosine phosphorylation (Fig. 3, b and g) and Ca2+ flux 
(Fig. 3 i). Importantly, although glNIH45-46 did not bind the 
426c Env (Fig. 2 b), it bound the mutant lacking the 276 
NLGS (apparent affinity of 0.7 µM; Fig. 2 e and Table S3) 
and the mutant lacking all three NLGS (apparent affinity of 
46 nM; Fig. 2 k and Table S3).
We also examined the interactions between these Envs 
and glVRC01, a clonal variant of the NIH45-46 antibody 
(Scheid et al., 2011). Even stronger binding affinities were 
observed with the glVRC01 antibody (Fig. 2, f and l; and 
Table S3). In all cases, the increase in the on-rates, rather than 
decrease in the off-rates, observed when the NLGS are removed 
staining with APC-labeled monoclonal anti–human IgG. Error bars represent SD from the mean of two independent experiments (b–f). B cells expressing the  
mature (b), germline-reverted NIH45-46 (c), and germline-reverted VRC01 (d) IgG BCR, as well as the germline-reverted NIH45-46 (e), and germline-reverted 
VRC01 (f) IgM BCR were either unstimulated, or were stimulated with the indicated 426c Env variants (40 µg/ml for the mature BCR, or 200 µg/ml for the germ-
line-reverted BCRs). Lysates were separated by SDS-PAGE, transferred to nitrocellulose, and stained with the mouse anti-phosphotyrosine mAb 4G10 (top) and a 
rabbit anti–-actin mAb 13E5 (bottom), followed by IRDye 800CW-labeled goat anti–mouse and IRDye 680LT-labeled goat anti–rabbit antibodies. Black arrows 
indicate proteins that show an increase in tyrosine phosphorylation. (g) Quantification of tyrosine phosphorylation signal corresponding to protein band in b–d 
are denoted with #. White bars, mature NIH45-46; black bars, germline NIH45-46; gray bars, germline VRC01. (h) Quantification of tyrosine phosphorylation sig-
nal corresponding to protein band in e and f, denoted with arrow. Black bars (germline NIH45-46) and gray bars (germline VRC01). Signal intensity was normal-
ized to the actin loading controls, and expressed relative to the unstimulated cells. Error bars represent the SD from two (germline-reverted IgG and IgM VRC01) 
or three (mature and germline-reverted IgG and IgM NIH45-46) independent experiments. *, actin-normalized log-transformed signal intensities that are statisti-
cally different from the unstimulated controls using a repeated measures ANOVA methodology, followed by Tukey’s multiple comparisons test. (i–k) B cells ex-
pressing the mature NIH45-46 (i), germline-reverted NIH45-46 (j), or germline-reverted VRC01 (k) IgG BCR were loaded with Fluo-4 direct calcium indicator and 
stimulated with the indicated Env proteins. Black arrow indicates time of Env addition. (l) Model illustrating how NIH45-46 (transparent) clashes with glycans at 
gp120 residues 276 and 460 if glycans are conformationally relaxed in the absence of NIH45-46. (m) Model of NIH45-46 bound to gp120 with glycans removed 
from 276, 460, and 463 to eliminate potential antibody-glycan clash. Red, gp120; yellow, NIH45-46 contact residues on gp120; blue, NIH45-46 heavy chain;  
purple, NIH45-46 light chain; orange, glycan at 276; green, glycan at 460; cyan, glycan at 463; white, glycans at other positions.
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276 is highly conserved among circulating HIV-1 strains and 
only 5.0% of the Env sequences lack this glycosylation site. 
Interestingly, a higher proportion of clade C than clade B 
Envs lack this glycosylation site (7.4% of C and 2.0% of B). Even 
less frequent is the simultaneous absence of all three NLGS 
(3.1%). Potentially, viral clones with rare glycosylation patterns 
on Env emerge during infection and stimulate the germline-
reverted BCRs of VRC01 class antibodies, such as NIH45-46 
and VRC01, thus starting the process of antibody affinity mat-
uration that eventually leads to the development of broadly 
neutralizing antibody responses (Gray et al., 2011a; Mikell et al., 
2011). The rarity of circulating Envs lacking these NLGS may 
in part explain why VRC01 class antibody responses are elic-
ited only by a minority of those infected with HIV (Lynch 
et al., 2012). We note that the above NLGS mutations on the 
backbone of the 426c Env do not diminish the ability of that 
Env to mediate virus–cell entry (Fig. 4 d). We do not yet know 
whether all the naturally occurring Envs that lack those three 
NLGS bind glNIH45-46 and glVRC01. We also do not know 
whether the modifications we discuss here will always lead to 
glNIH45-46 or glVRC01 binding when introduced on the 
backbone of all the Envs we tested (Table S2). Most likely, 
they will not always result in antibody binding because addi-
tional structural elements of Env will vary in a backbone-specific 
manner and may limit antibody binding even in the absence 
of the three NLGS discussed here. Structural information of 
Envs that do and do not bind glNIH45-46 and glVRC01 
will be very useful to better understand why some Env are 
recognized by these antibodies and why some are not. Such 
structural studies will greatly assist Env-immunogen design 
efforts that are geared toward stimulating B cells expressing 
VRC01 class BCRs.
Despite the potent binding of other VRC01 class mem-
bers studied here (12A21, 3BNC60, and 3BNC117; Fig. 5 a) 
to the 426c Env lacking all three NLGS, their germline-reverted 
versions did not recognize that Env (Fig. 5 b). The heavy 
chains of mAbs NIH45-46, VRC01, 12A21, 3BNC60, and 
3BNC117 are derived from the same VH1-2*02 allele (Zhou 
et al., 2010; Scheid et al., 2011). However, the light chains 
of mAbs NIH45-46 and VRC01 are derived from Vk3-11, 
whereas those of 12A21, 3BNC60, and 3BNC117 are de-
rived from Vk1D-33. Structural differences between the light 
chains among these antibodies (Fig. S1) could be responsible 
for their different Env-recognition properties. Indeed, when 
the germline-reverted light chains of 12A21 and 3BNC60 were 
replaced by that of NIH45-46/VRC01, the chimeric germline-
reverted antibodies recognized the 426c NLGS mutant Envs 
(Fig. 5, c and d). Thus, the mutations in loop D and the V5 
region identified here may be the minimal set of mutations 
allowing the binding of germline VRC01 class antibodies to 
the CD4-BS. It will be important to identify additional Env 
mutations that alleviate clashes between the germline-reverted 
light chains of antibodies such as 12A21 or 3BNC60 and ele-
ments of Env.
Our experiments indicate that a potential reason for the 
lack of elicitation of VRC01 antibodies, by Env immunogens 
mVRC01 have a two-residue deletion relative to the germline-
reverted antibodies (Fig. S1; Zhou et al., 2010; Diskin et al., 
2011; Scheid et al., 2011) and this difference may result in dif-
ferential interactions with the NLGS at positions 276 and 460. 
Future studies will reveal whether or not similar mutations on 
different Envs also lead to glNIH45-46 or glVRC01 binding.
In accordance with the aforementioned antibody Env-
binding results, mNIH45-46 neutralized 426c viruses express-
ing the deglycosylated Env variants more efficiently than the 
parental virus (Fig. 4 a), whereas glNIH45-46 weakly neutral-
ized viruses expressing either the single (276 NLGS) or triple 
NLGS mutant Envs, but not viruses expressing WT or Env 
lacking the 460 and 463 NLGS (Fig. 4 b). The NLGS at position 
Figure 4. Neutralization of 426c viral variants by NIH45-46.  
(a and b)Entry of pseudovirions expressing either the wild-type 426c Env 
or derivatives lacking NLGS at positions 276, 460, and 463 into TZM-bl  
cells was measured in the presence of mature (a) or germline-reverted  
(b) NIH45-46 IgG. Pseudovirions expressing the unrelated murine leukemia 
virus (MLV) envelope are included as controls. Entry of the indicated 
pseudovirions into TZM-bl cells in the presence of mAb PG9 was used as 
control for nonspecific neutralization that may sometimes occur at high 
mAb concentrations (c). Each data point represents the mean ± SEM of 
relative luciferase units of two independent experiments, each done in 
duplicate. (d) Single-round entry competent pseudovirions expressing the 
indicated 426c Env were added to TZMbl cells in a 96-well microtiter plate 
at 0.1 ng/ well p24 (n = 6; open bars), and 1 ng/ well p24 (n = 6; filled 
bars). Bars represent the mean ± SEM of relative luciferase units  
expressed relative to that obtained with the wild-type virus (n = 6).
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(Cellgro) supplemented with 10% FBS, 2 mM l-glutamine, 100 U/ml peni-
cillin, and 100 µg/ml streptomycin. For neutralization assays, the cells were 
plated at a density of 5 × 104 cells per well 24 h before addition of virus and 
antibody. Antibodies were serially diluted in microtiter wells at the indicated 
starting concentration in a total volume of 30 µl per well. 30 µl of virus (pre-
viously determined to result in 2 × 105 luciferase units) was added to each 
well containing the titrated antibodies. Antibody-virus mixtures in duplicate 
wells were incubated at 37°C for 1.5 h. During the last 30 min of the incuba-
tion, cells were treated at 37°C with 1 µg/ml of polybrene. The polybrene was 
then aspirated from the cells and replaced with 50 µl of antibody-pseudovirus 
mixture. Plates were incubated at 37°C for 72 h, media was aspirated, and 
cells were lysed to measure luciferase activity using Steady-Glo Luciferase 
Reagent (Promega)
ELISA. Env ELISA assays were performed with established methodologies, 
either by directly adsorbing recombinant Env (SIVmac239, JRCSF, BAL, 
Consensus C, DU151, Consensus A1, MJ613, and A244; Immune Tech-
nologies) to ELISA plates or by capturing p120 released from pseudoviruses 
after lysis by 1% Triton X-100 on D7324-coated (anti–C-terminal gp120 
sheep antibody) ELISA wells. In the first case, the binding cut off for ELISA 
was defined as the mean + 3 SD of A450 recorded with the SIVmac gp120 at 
the highest antibody concentration, whereas in the second case the binding 
cut off was the mean + 3 SD of the absorbance obtained for each antibody 
against the capture antibody alone (no Env).
Biolayer interferometry analysis of mAb-Env binding. These assays 
were performed on the Octet KQe instrument (ForteBio, Inc.). IgGs (20 µg/ml 
in PBS) were immobilized onto anti–human IgG FC capture (AHC) biosen-
sors (ForteBio) for 5 min. The baseline interference was then read for 60 s, in 
kinetics buffer (KB: 1× PBS, 0.01% BSA, 0.02%, Tween 20, and 0.005% 
NaN3),followed by subsequent immersion of the sensors into wells contain-
ing recombinant trimeric Env gp140 diluted in KB for 300s (association 
phase). Sensors were then immersed in KB for the indicated times (dissocia-
tion phase). All kinetic interactions were measured with new sensors at 30°C 
and shaking at 1,000 RPM in 96-well plates. Curve fitting was done using a 
1:1 binding model using the Data analysis software (ForteBio) and using the 
concentration of gp140 protomers in solution. Mean kon and koff and apparent 
Kd values were determined from all binding curves that matched the theoret-
ical fit with an R2 value of ≥0.95.
HIV envelopes. The following Envs were examined: clade A: Q168a2, 
Q259d2, Q461e2, Q769h5; clade B: SF162, SF162V1, SF162V2, 
is the inability of these immunogens to stimulate B cells ex-
pressing the germline BCRs of such antibodies and initiate 
the maturation process that leads to the production of bNAbs 
against one of the most conserved HIV Env regions. We show 
that glycosylation of specific Env regions hinders recognition 
by the germline-reverted BCRs of two of the most potent 
VRC01 class antibodies. As such, our findings provide a path-
way to overcome a crucial, early, roadblock in the elicitation 
of similar antibodies by immunization. We note that additional 
blocks may prevent the elicitation of such antibodies during im-
munization and that potentially prime boost immunization strat-
egies need to be devised to guide BCR evolution toward specific 
B cell maturation pathways that are necessary for the produc-
tion of VRC01 class antibodies (Kwong and Mascola, 2012).
MATERIALS AND METHODS
Antibodies and BCR construction. The anti–CD4-BS mAbs discussed 
here were isolated from different HIV-infected subjects by VH+VL gene 
amplification from single B cells (Wu et al., 2010; Scheid et al., 2011). Solu-
ble IgGs were expressed in 293F cells and purified by Protein A affinity chro-
matography. Mature and germline-reverted IgG forms of VRC01 were provided 
by J. Mascola and X. Wu (National Institutes of Health, Bethesda, MD).
To generate plasmids expressing the membrane-anchored forms of the 
anti-HIV antibodies, the following strategy was used. The variable heavy 
and light antibody regions (separated by a furin cleavage site and an F2A 
peptide sequence) were inserted into pTT5 vector. The constant IgG and 
IgM splice variant cDNAs (containing the two exons that encode the trans-
membrane and cytoplasmic domains of human IgG and IgM) were synthe-
sized by GenScript. That sequence was introduced 3 to the variable heavy 
region in the aforementioned pTT5 vector. These vectors express the mem-
brane-anchored version of either the mature or germline-reverted versions 
of the antibodies studied here.
Cells. The DG-75 human Burkitt’s lymphoma (#CRL-2625; ATCC) cell 
line was maintained in RPMI-1640 supplemented with 10% FBS. DG-75 
cells express human IgM do not express Fc receptors.
Neutralization assays. Neutralization assays were performed as previously 
described (Saunders et al., 2005). TZM-bl cells were maintained in DMEM 
Figure 5. Binding of mature and germline-reverted 
anti–CD4-BS bnmAbs to the 426 Env lacking NLGS at 
positions 276, 460, and 463. Binding of the mature (a) and 
germline-reverted (b) antibodies to 426c Env lacking all three 
NLGS at a concentration of 1 µM was measured by BLI.  
Binding of the germline-reverted NIH45-46 light chain with 
the germline-reverted 3BNC60/3BNC117 heavy chain (c) and 
the germline-reverted NIH45-46 light chain with the  
germline-reverted 12A21 heavy chain (d) to the indicated 
trimeric Env was measured by BLI. All Env were tested at 
concentration of 1 µM.
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50 HIV-1+ subjects. After centrifugation and washing (2× in ice cold FACS 
wash buffer), the cells were resuspended in 200 µl of 1% paraformaldehyde 
and analyzed on an LSR II cytometer (BD). Envelope surface staining was 
expressed as the MFI of PE staining in the presence of Env + HIV Ig PE 
minus the MFI obtained with HIV-IgG-PE alone on BCR expressing 
(APC-positive) cells.
Env mutagenesis. Point mutations in the gp140 and gp160 envelope se-
quences were introduced by site-directed mutagenesis (Stratagene Quick 
Change II system from Agilent Technologies, Santa Clara, California), using the 
following primers (sense strand provided) 426c-N460D/N463D (5-GAT-
GGGGGAAACACTACCGATAACACCGAGATTTCC-3) and 426c-N276D 
(5-GAGGAAGAGATTGTGATCAGATCAAAAGACCTGAGCGAT-
AAT-3).
Modeling the NIH45-46-Env interaction. A homology model for core 
gp120 of clade C strain 426c was built by RosettaRemodel (Huang et al., 
2011), using the NIH45-46-gp120 crystal structure (PDB accession no. 3u7y) 
as a structural template. Low-energy backbone conformations were gener-
ated for the V5 loop in the presence of bound NIH45-46. Representative 
Man8GlcNac2 glycans were then aligned onto each gp120 Asn residue within 
a glycosylation sequon, and low-energy glycan conformations were mod-
eled using GlycanRelax (Schief et al., 2009).
Statistical analysis. Significant increase of tyrosine phosphorylation was 
assessed by repeated measures ANOVA followed by Tukey’s multiple com-
parisons test comparing log-transformed, actin-normalized Western blot sig-
nal intensities of antigen-stimulated cells with that of unstimulated cells. 
A p-value <0.05 was considered significant.
Online supplemental material. Fig. S1 shows amino acid alignment of the 
germline-reverted antibody heavy and light chains. Table S1 shows characteristics 
of VRC01 class antibodies. Table S2 shows IgG binding to recombinant Env 
proteins. Table S3 shows the binding kinetics of mature and germline NIH 
45-46 IgG to trimeric 426c Env gp140 variants. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20122824/DC1.
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